Share This Page
Suppliers and packagers for mekinist
✉ Email this page to a colleague
mekinist
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | SOLUTION;ORAL | 217513 | NDA | Novartis Pharmaceuticals Corporation | 0078-1161-47 | 90 mL in 1 BOTTLE (0078-1161-47) | 2023-03-16 |
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114 | NDA | Novartis Pharmaceuticals Corporation | 0078-1105-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-1105-15) | 2016-03-17 |
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114 | NDA | Novartis Pharmaceuticals Corporation | 0078-1112-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-1112-15) | 2016-03-17 |
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114 | NDA | Novartis Pharmaceuticals Corporation | 0078-1112-94 | 14 TABLET, FILM COATED in 1 BOTTLE (0078-1112-94) | 2016-03-17 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Mekinist
Introduction
Mekinist (trametinib) is a targeted cancer therapy developed by Novartis, primarily used for treating BRAF-mutant melanoma and other solid tumors. As a kinase inhibitor targeting MEK1/2 pathways, Mekinist has garnered significant attention in oncology therapeutics. Understanding its supply chain dynamics, including key manufacturers, authorized distributors, and secondary suppliers, is critical for stakeholders involved in procurement, logistics, and regulatory compliance.
This report delves into the primary suppliers of Mekinist, examining manufacturing sources, distribution channels, regulatory considerations, and market access. Ensuring supply chain integrity for this high-value pharmaceutical product is pivotal for maintaining treatment continuity across global healthcare systems.
Manufacturing and Original Development
Novartis as the Proprietary Manufacturer
Novartis Pharmaceuticals is the original developer, manufacturing, and marketing Mekinist. The company's global manufacturing facilities, spread across North America, Europe, and Asia, handle the production of active pharmaceutical ingredients (APIs) and finished dosage forms. Novartis maintains strict quality control and regulatory compliance to meet the standards set by agencies such as the FDA, EMA, and other regulatory bodies.
API Production
While Novartis manages the supply chain for Mekinist's final formulation, it often sources API components from specialized contract manufacturing organizations (CMOs). These CMOs specialize in high-quality chemical synthesis and API certification, adhering to Good Manufacturing Practices (GMP). Details about specific API suppliers are proprietary but generally involve well-established chemistry firms with proven regulatory track records.
Authorized Distributors and Supply Chain Partners
Novartis Global Distribution Network
Novartis distributes Mekinist through a comprehensive network of authorized distributors and wholesalers. These entities operate within strict regulatory frameworks to ensure product safety, traceability, and integrity. Notable distribution channels include:
- Global pharmaceutical wholesalers like McKesson, Cardinal Health, and AmerisourceBergen.
- Regional distributors, which may have exclusive rights within specific territories, such as Europe, Asia-Pacific, and Latin America.
- Hospital and specialty pharmacy supply chains, which handle direct distribution to oncology centers.
Regulatory Compliance
Distributors must adhere to Good Distribution Practice (GDP) standards, ensuring cold chain management, proper storage, and transportation conditions. These standards are enforced by agencies like the FDA (USA), EMA (EU), and corresponding local authorities.
Secondary Suppliers and Gray Market Channels
Secondary Suppliers
Post patent-expiry or in markets with limited availability, secondary or grey market suppliers may introduce Mekinist via authorized or unauthorized channels. These include regional importers and regional generic manufacturers, although Mekinist remains under patent protection, limiting licensed generic competition.
Legal Generic and Biosimilar Market
As of the knowledge cutoff in 2023, no generic or biosimilar versions of trametinib have received regulatory approval, largely owing to patent protections and complex manufacturing requirements. However, patent litigation and exclusivity periods influence market entry timelines, affecting the number of suppliers actively distributing Mekinist.
Risks Associated with Unauthorized Sources
Unregulated supply channels pose risks for counterfeit or substandard medication, compromising patient safety. Stakeholders must verify authenticity through provenance documentation and supply chain audits.
Regulatory and Patent Considerations Affecting Suppliers
Patent Landscape
Mekinist’s patent protection, initially granted in the early 2010s, provided exclusivity until approximately 2025 in major markets. These protections restrict generic manufacturers from producing and marketing equivalent trametinib formulations, limiting the number of authorized suppliers.
Regulatory Approvals
Manufacturers and distributors must comply with international and local regulatory approvals before supplying Mekinist. These include submission of Manufacturing Authorization (MA) and product registration dossiers.
Supply Chain Transparency
Regulatory agencies and pharmaceutical companies emphasize supply chain transparency to prevent diversion and ensure product quality. Track-and-trace systems, such as serialization and barcoding, are mandated in many jurisdictions.
Emerging Market Dynamics
Market Access and Local Suppliers
In emerging markets, authorized regional distributors often partner with local manufacturers to meet local regulatory requirements, price sensitivities, and distribution challenges. These agreements can lead to the inclusion of third-party suppliers, especially where local manufacturing licenses are granted or cooperative agreements exist.
Potential for Manufacturing Partnerships
Novartis might engage with Contract Manufacturing Organizations (CMOs) or license manufacturing rights to regional entities to scale supply as demand grows, especially in markets with high unmet needs or during supply shortages.
Conclusion
The primary and most reliable supplier of Mekinist remains Novartis, which maintains strict control over API sourcing, manufacturing, and distribution channels. Globally, distribution is managed through authorized wholesalers that comply with international GMP and GDP standards, ensuring product integrity.
While patent protections restrict the entry of generic manufacturers, emerging market dynamics and patent expirations could alter the supplier landscape. Continuous monitoring of patent status, regulatory approvals, and supply chain integrity will be essential for stakeholders seeking secure and reliable procurement of Mekinist.
Key Takeaways
- Main Supplier: Novartis directly manufactures and distributes Mekinist globally, maintaining stringent quality control standards.
- API Sourcing: API components are sourced from specialized CMOs under GMP regulations, though specific suppliers remain proprietary.
- Distribution Network: Robust authorized distribution networks, including major global wholesalers, ensure supply continuity; strict compliance with GDP standards is enforced.
- Market Exclusivity: Patent protections limit generic competition until approximately 2025; patent expiry could diversify supply sources.
- Supply Chain Risks: Counterfeit risks exist via gray markets; organizations should implement traceability measures and verify sourcing to mitigate these risks.
FAQs
1. Who manufactures Mekinist?
Novartis Pharmaceuticals is the original and primary manufacturer of Mekinist, overseeing production, quality assurance, and global distribution.
2. Are there generic versions of Mekinist available?
As of 2023, no generic versions have been approved due to patent protections, but patent expiry around 2025 could open the market for biosimilars and generics.
3. How is Mekinist distributed worldwide?
Distribution occurs through authorized global wholesalers, regional distributors, and direct supply chains to healthcare providers, all adhering to international regulatory standards.
4. What are the risks of sourcing Mekinist from secondary suppliers?
Risks include counterfeit products, substandard quality, and supply chain violations. Stakeholders should verify provenance and compliance documentation.
5. Will patent expiration lead to more suppliers?
Yes. Patent expiry typically allows generic manufacturers to enter the market, increasing supplier diversity and potentially reducing costs.
Sources:
[1] Novartis. Mekinist (trametinib) prescribing information.
[2] FDA. Drug Approvals and Inventories.
[3] European Medicines Agency. Marketing authorization of Mekinist.
[4] Market reports on biosimilar landscape (2022).
[5] World Health Organization. Good Distribution Practices (GDP) guidelines.
More… ↓
